Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Visen Pharmaceuticals (维升药业) IPO: PHIP Updates Don't Look Positive

Pharmaceuticals (维升药业) IPO: Valuation and Book Building

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

VISEN Pharmaceuticals / Equity Capital Markets

<ul>
<li>Visen Pharmaceuticals is looking at raising up to USD 300m to list in Hong Kong.</li>
<li>We look at the company’s core product and highlight two unfavorable trends.</li>
<li>We are not excited about the company’s fundamentals, and are not keen in the deal.</li>
</ul>


Visen Pharmaceuticals is looking at raising up to USD 300m to list in Hong Kong.
We look at the company’s core product and highlight two unfavorable trends.
We are not excited about the company’s fundamentals, and are not keen in the deal.


Anhui Anke Biotechnology (Group) (300009 CH)

Visen Pharmaceuticals IPO: Unfavorable Trends